What are the best medications for Parkinson’s disease other than Akidin and Rivotril?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Best Medications for Parkinson's Disease (Excluding Akidin and Rivotril)

Levodopa remains the gold-standard medication for Parkinson's disease and should be your first-line choice for most patients, particularly those over 60 years or with moderate-to-severe symptoms. 1, 2, 3

Primary Treatment Options

Levodopa (First-Line for Most Patients)

Levodopa is the most effective medication available for treating motor symptoms of Parkinson's disease and eventually becomes necessary for most patients regardless of initial therapy 1, 3. It provides superior symptomatic control compared to all other agents.

When to start with levodopa:

  • Patients over 60 years of age
  • Moderate to severe motor symptoms at any age
  • Significant functional impairment affecting daily activities
  • Patients with multiple comorbidities 1

Dosing approach: Start with carbidopa-levodopa 25/100 mg three times daily, taken 30 minutes before meals to optimize absorption 4. Titrate based on symptom control.

Critical consideration for protein intake: Patients experiencing motor fluctuations should follow a protein-redistribution diet—consume low-protein meals at breakfast and lunch, reserving protein-rich foods for dinner only. This maximizes levodopa absorption and efficacy by reducing competition with dietary amino acids 4.

Alternative Initial Therapies (For Specific Situations)

Dopamine agonists (pramipexole, ropinirole, rotigotine patch) can be considered for:

  • Younger patients (under 60 years) with mild symptoms
  • Patients wishing to delay levodopa-related motor complications 1, 5

However, these agents are less effective than levodopa and carry risks including impulse control disorders (compulsive gambling, shopping, hypersexuality) in 6-17% of patients 6.

MAO-B inhibitors (rasagiline, selegiline) are options for:

  • Early, mild disease
  • Adjunct therapy to levodopa 1, 5, 3

Zonisamide is clinically useful as adjunct therapy in early/stable PD 5.

Managing Motor Complications

For Motor Fluctuations ("Wearing-Off")

When patients develop fluctuations between "on" (good symptom control) and "off" (symptom return) states:

  1. Optimize levodopa dosing: Increase frequency or adjust timing
  2. Add adjunct medications:
    • COMT inhibitors (entacapone, opicapone) 5, 7
    • MAO-B inhibitors (rasagiline) 5
    • Dopamine agonists 5
    • Safinamide 5

For Dyskinesia (Involuntary Movements)

Amantadine is the only FDA-approved medication specifically for levodopa-induced dyskinesia and should be your first choice 5, 8, 9. Extended-release amantadine (ADS-5102) shows superior efficacy but has higher adverse event rates 8.

Dosing: Immediate-release amantadine 100 mg twice daily, can increase to 300-400 mg/day divided 8.

Alternative: Clozapine is clinically useful but requires monitoring for agranulocytosis 5.

Advanced Disease Options

For patients with severe motor fluctuations or medication-resistant symptoms:

  • Deep brain stimulation (GPi or STN targets) 5, 8
  • Levodopa-carbidopa intestinal gel infusion 5, 7
  • Subcutaneous apomorphine infusion 7

Non-Motor Symptom Management

For cognitive impairment: Rivastigmine (cholinesterase inhibitor) 10, 3

For depression: Pramipexole or standard antidepressants 3

For REM sleep behavior disorder: Clonazepam 0.25-2 mg at bedtime or melatonin 3-12 mg at bedtime 11, 12, 13

For psychosis/hallucinations: Clozapine (requires monitoring) or quetiapine at low doses 10

Critical Safety Warnings

Avoid these combinations:

  • Dopamine agonists in patients with dementia with Lewy bodies (can cause fatal sensitivity reactions) 10
  • Antipsychotics in Lewy body dementia (50% risk of severe reactions) 10
  • Abrupt discontinuation of dopamine agonists (can cause severe withdrawal, mood disturbances, suicidal ideation) 6

Note on "Akidin" and "Rivotril": The evidence provided shows Rivotril (clonazepam) is actually used for REM sleep behavior disorder in Parkinson's patients, not as primary PD treatment 11, 12. "Akidin" appears to be a misidentification—no such medication exists for Parkinson's disease in the medical literature provided.

References

Research

Pharmacological Treatment of Early Motor Manifestations of Parkinson Disease (PD).

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2020

Guideline

espen guideline clinical nutrition in neurology.

Clinical Nutrition, 2018

Research

Treatment for Dyskinesia in Parkinson's Disease: A Network Meta-analysis of Randomized Controlled Trials.

Movement disorders : official journal of the Movement Disorder Society, 2025

Guideline

dementia in older people: an update.

Internal medicine journal, 2014

Guideline

management of rem sleep behavior disorder: an american academy of sleep medicine clinical practice guideline.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2023

Guideline

best practice guide for the treatment of rem sleep behavior disorder (rbd).

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.